-transparent.png){kind=logo}
In this randomized trial 151 patients with locally advanced prostatic carcinoma (T3-4 M0) were treated with orchiectomy, estrogens or radiotherapy. In comparison of these therapy modalities attention was paid to the progression free survival and to the complications associated with these therapies. There was no significant difference in the progression free survival during the four-year follow-up period. The frequency of cardiovascular complications was highest in the estrogen group, where 13 of 50 patients had 19 complications. In the radiotherapy group 19 of 45 patients had bowel or bladder complications.
Related Publications
J Aro, and
R Haapiainen, and
M Kajanti, and
S Rannikko, and
O Alfthan
May 1991,
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
J Aro, and
R Haapiainen, and
M Kajanti, and
S Rannikko, and
O Alfthan
January 2005,
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
J Aro, and
R Haapiainen, and
M Kajanti, and
S Rannikko, and
O Alfthan
April 1998,
Tijdschrift voor gerontologie en geriatrie,
J Aro, and
R Haapiainen, and
M Kajanti, and
S Rannikko, and
O Alfthan
February 1994,
Urology,
J Aro, and
R Haapiainen, and
M Kajanti, and
S Rannikko, and
O Alfthan
January 1989,
Progress in clinical and biological research,
J Aro, and
R Haapiainen, and
M Kajanti, and
S Rannikko, and
O Alfthan
October 1987,
The Journal of urology,
J Aro, and
R Haapiainen, and
M Kajanti, and
S Rannikko, and
O Alfthan
December 1985,
Wiener medizinische Wochenschrift (1946),
J Aro, and
R Haapiainen, and
M Kajanti, and
S Rannikko, and
O Alfthan
January 1980,
Acta urologica Belgica,
J Aro, and
R Haapiainen, and
M Kajanti, and
S Rannikko, and
O Alfthan
November 1997,
Seminars in urologic oncology,
J Aro, and
R Haapiainen, and
M Kajanti, and
S Rannikko, and
O Alfthan
March 1991,
The Journal of urology,
